Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 586

1.

Symptom prevalence, bother, and treatment satisfaction in men with lower urinary tract symptoms in Southeast Asia: a multinational, cross-sectional survey.

Ho LY, Chu PS, Consigliere DT, Zainuddin ZM, Bolong D, Chan CK, Eng M, Huynh DN, Kochakarn W, Lapitan MCM, Le DK, Le QD, Lee F, Lojanapiwat B, Nguyen BN, Ong TA, Reyes BJ, Santingamkun A, Tsang WC, Abrams P.

World J Urol. 2017 Oct 19. doi: 10.1007/s00345-017-2097-2. [Epub ahead of print]

PMID:
29051978
2.

Reply to Bora Lee and Jae Heon Kim's Letter to the Editor re: Alan D. Uren, Nikki Cotterill, Christopher Harding, et al. Qualitative Exploration of the Patient Experience of Underactive Bladder. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.03.045.

Uren AD, Cotterill N, Harding C, Hillary C, Chapple C, Klaver M, Bongaerts D, Hakimi Z, Abrams P.

Eur Urol. 2017 Aug 8. pii: S0302-2838(17)30666-8. doi: 10.1016/j.eururo.2017.07.037. [Epub ahead of print] No abstract available.

PMID:
28801128
3.

Reply from Authors re: Mikkel Fode, Jens S√łnksen. Towards a Greater Understanding of Underactive Bladder. Eur Urol 2017;72:408-9.

Uren AD, Cotterill N, Harding C, Hillary C, Chapple C, Klaver M, Bongaerts D, Hakimi Z, Abrams P.

Eur Urol. 2017 Sep;72(3):409-410. doi: 10.1016/j.eururo.2017.06.039. Epub 2017 Jul 13. No abstract available.

PMID:
28712857
4.

Correction: Prediction of Impending Type 1 Diabetes through Automated Dual-Label Measurement of Proinsulin:C-Peptide Ratio.

Van Dalem A, Demeester S, Balti EV, Keymeulen B, Gillard P, Lapauw B, De Block C, Abrams P, Weber E, Vermeulen I, De Pauw P, Pipeleers D, Weets I, Gorus FK; Belgian Diabetes Registry.

PLoS One. 2017 Jun 1;12(6):e0179108. doi: 10.1371/journal.pone.0179108. eCollection 2017.

5.

The use of intravesical gentamicin to treat recurrent urinary tract infections in lower urinary tract dysfunction.

Abrams P, Hashim H, Tomson C, Macgowan A, Skews R, Warren K.

Neurourol Urodyn. 2017 Nov;36(8):2109-2116. doi: 10.1002/nau.23250. Epub 2017 May 15.

PMID:
28503891
6.

Do we assess urethral function adequately in LUTD and NLUTD? ICI-RS 2015.

Gajewski JB, Rosier PFWM, Rahnama'i S, Abrams P.

Neurourol Urodyn. 2017 Apr;36(4):935-942. doi: 10.1002/nau.23100. Review.

PMID:
28444713
7.

Male bladder outlet obstruction: Time to re-evaluate the definition and reconsider our diagnostic pathway? ICI-RS 2015.

Rademakers K, Drake MJ, Gammie A, Djurhuus JC, Rosier PFWM, Abrams P, Harding C.

Neurourol Urodyn. 2017 Apr;36(4):894-901. doi: 10.1002/nau.23178. Review.

PMID:
28444709
8.

The role of male slings in post prostatectomy incontinence: ICI-RS 2015.

Sahai A, Abrams P, Dmochowski R, Anding R.

Neurourol Urodyn. 2017 Apr;36(4):927-934. doi: 10.1002/nau.23264. Review.

PMID:
28444702
9.

Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study).

Herschorn S, Chapple CR, Abrams P, Arlandis S, Mitcheson D, Lee KS, Ridder A, Stoelzel M, Paireddy A, van Maanen R, Robinson D.

BJU Int. 2017 Oct;120(4):562-575. doi: 10.1111/bju.13882. Epub 2017 Jun 8.

PMID:
28418102
11.

Qualitative Exploration of the Patient Experience of Underactive Bladder.

Uren AD, Cotterill N, Harding C, Hillary C, Chapple C, Klaver M, Bongaerts D, Hakimi Z, Abrams P.

Eur Urol. 2017 Sep;72(3):402-407. doi: 10.1016/j.eururo.2017.03.045. Epub 2017 Apr 8.

PMID:
28400168
12.

Prediction of Impending Type 1 Diabetes through Automated Dual-Label Measurement of Proinsulin:C-Peptide Ratio.

Van Dalem A, Demeester S, Balti EV, Keymeulen B, Gillard P, Lapauw B, De Block C, Abrams P, Weber E, Vermeulen I, De Pauw P, Pipeleers D, Weets I, Gorus FK; Belgian Diabetes Registry.

PLoS One. 2016 Dec 1;11(12):e0166702. doi: 10.1371/journal.pone.0166702. eCollection 2016. Erratum in: PLoS One. 2017 Jun 1;12 (6):e0179108.

13.

Mirabegron in overactive bladder patients: efficacy review and update on drug safety.

Warren K, Burden H, Abrams P.

Ther Adv Drug Saf. 2016 Oct;7(5):204-216. Epub 2016 Jul 19. Review.

14.

Air filled, including "air-charged," catheters in urodynamic studies: does the evidence justify their use?

Abrams P, Damaser MS, Niblett P, Rosier PFWM, Toozs-Hobson P, Hosker G, Kightley R, Gammie A.

Neurourol Urodyn. 2017 Jun;36(5):1234-1242. doi: 10.1002/nau.23108. Epub 2016 Aug 31. Review.

PMID:
27580083
15.

Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY).

Abrams P, Kelleher C, Staskin D, Kay R, Martan A, Mincik I, Newgreen D, Ridder A, Paireddy A, van Maanen R.

World J Urol. 2017 May;35(5):827-838. doi: 10.1007/s00345-016-1908-1. Epub 2016 Aug 11.

PMID:
27514371
16.

Psychometric equivalence of electronic and telephone completion of the ICIQ modules.

Uren AD, Cotterill N, Parke SE, Abrams P.

Neurourol Urodyn. 2017 Jun;36(5):1342-1349. doi: 10.1002/nau.23103. Epub 2016 Aug 11.

PMID:
27513627
17.

Hydra effects in stable communities and their implications for system dynamics.

Cortez MH, Abrams PA.

Ecology. 2016 May;97(5):1135-45.

PMID:
27349091
18.

Estimation of bladder contractility from intravesical pressure-volume measurements.

Fry CH, Gammie A, Drake MJ, Abrams P, Kitney DG, Vahabi B.

Neurourol Urodyn. 2017 Apr;36(4):1009-1014. doi: 10.1002/nau.23047. Epub 2016 Jun 6.

19.

Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array.

Saunders EJ, Dadaev T, Leongamornlert DA, Al Olama AA, Benlloch S, Giles GG, Wiklund F, Gronberg H, Haiman CA, Schleutker J, Nordestgaard BG, Travis RC, Neal D, Pasayan N, Khaw KT, Stanford JL, Blot WJ, Thibodeau SN, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Brenner H, Park JY, Kaneva R, Batra J, Teixeira MR, Pandha H, Govindasami K, Muir K; UK Genetic Prostate Cancer Study Collaborators; UK ProtecT Study Collaborators; PRACTICAL Consortium, Easton DF, Eeles RA, Kote-Jarai Z.

Br J Cancer. 2016 Apr 12;114(8):945-52.

20.

Prostate cancer - evidence of exercise and nutrition trial (PrEvENT): study protocol for a randomised controlled feasibility trial.

Hackshaw-McGeagh L, Lane JA, Persad R, Gillatt D, Holly JM, Koupparis A, Rowe E, Johnston L, Cloete J, Shiridzinomwa C, Abrams P, Penfold CM, Bahl A, Oxley J, Perks CM, Martin R.

Trials. 2016 Mar 7;17(1):123. doi: 10.1186/s13063-016-1248-x.

Supplemental Content

Loading ...
Support Center